Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FMDW3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on November 12, 2025, represents a continuation of DMS Pharmaceutical Group's role as a critical supplier within the federal pharmaceutical supply chain. The contract carries no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The award is structured under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group was awarded its prime vendor contract under PPV-G GEN V on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036. This indefinite delivery vehicle authorizes DLA to issue firm fixed-price delivery orders for an extensive portfolio of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The company's product offerings span oncology treatments, immunosuppressants, emergency medications, specialty surgical products, and routine pharmaceuticals, positioning it to serve as a key regional pharmaceutical supplier for Department of Defense healthcare operations globally. The PPV-G GEN V structure includes a 30-month base period with three 30-month option periods and establishes DMS Pharmaceutical Group as one of multiple prime vendor contractors supporting military medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FMDW3?
SPE2DR26FMDW3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FMDW3 worth?
The government has obligated $15,792 on SPE2DR26FMDW3.
Is contract SPE2DR26FMDW3 an order under another contract?
Yes. SPE2DR26FMDW3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDW3 competed?
The extent of competition for SPE2DR26FMDW3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award